title: Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
abstract: OBJECTIVE
  The aim of the study was to evaluate the activity and safety of reduced-dose abiraterone acetate (AA) in ≥ 85 year-old patients with advanced castrate-resistant prostate cancer (CRPC).
  
  
  METHODS
  Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily.
  
  
  RESULTS
  Twenty-six patients were enrolled; median age was 88 years (range=85-93). Prostate-specific antigen (PSA) response was observed in 18 (69.2%) subjects, median time to PSA progression was 6.4 months (95% confidence interval (CI)=2.8-8.8) and median overall survival was 14.3 months (95% CI=7.2-18.3). The treatment was well-tolerated and adverse events, related to mineralocorticoid excess, were of grade 1-2 in all patients.
  
  
  CONCLUSIONS
  Reduced dose of AA combined with a very low dose of prednisone is effective and well-tolerated in very elderly patients with advanced CRPC.
authors.affiliation: Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy r.petrioli@ao-siena.toscana.it.
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.affiliation: Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome, Italy.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
authors.affiliation: Pharmacology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
authors.forename: Anna Ida
authors.initials: AI
authors.lastname: Fiaschi
authors.affiliation: Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
authors.forename: Letizia
authors.initials: L
authors.lastname: Laera
authors.affiliation: Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
authors.forename: Salvatora Tindara
authors.initials: ST
authors.lastname: Miano
authors.affiliation: Urology Unit, Department of Genitourinary Diseases, University of Siena, Siena, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: De Rubertis
authors.affiliation: Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
mesh_terms: D000069501:Abiraterone Acetate; D000369:Aged, 80 and over; D000736:Androstenes / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage*; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D000736:Androstenes; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate; D011241:Prednisone
keywords: Abiraterone; PSA; castrate-resistant; elderly; prostate cancer